Pulmonary complications of antiviral drugs (Sofosbuvir and Daclatasvir) used in treatment of patients with chronic hepatitis C virus | ||||
| Al-Azhar International Medical Journal | ||||
| Article 14, Volume 1, Issue 3, March 2020, Page 314-318 PDF (543.63 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/aimj.2020.21180.1132 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Eid Mohammed Mahmoud Mohammed   1; Ibrahim Abd-Elfattah Mohsen2; Talaat Abd-Elaziz Arafa2; Diaa Mohammed Elteiby3
| ||||
| 1Chest department, faculty of medicine, Al-Azhar University, Cairo, Egypt | ||||
| 2Chest department, faculty of medicine, Al-Azhar University, Cairo | ||||
| 3Endemic diseases and Tropical Medicine department, faculty of medicine, Al-Azhar University, Cairo | ||||
| Abstract | ||||
| Background: Egypt has one of the highest hepatitis C virus (HCV) prevalence rates in the world, which led the government to strive to control it. The national guidelines for chronic HCV treatment had been modified to be interferon-free regimens by giving, the pan-genotypic direct acting antiviral agents (DAAs), sofosbuvir plus daclatasvir with or without ribavirin regimen. Aim of the study: Evaluation of the development of any considerable pulmonary complications among Egyptian patients receiving the combination of sofosbuvir plus daclatasvir for the treatment of chronic HCV infection. Patients and Methods: The study included fifty patients with chronic HCV who were planned to be treated with sofosbuvir plus daclatasvir regimen. They were followed up during the course of the treatment to report and diagnose any developed respiratory symptoms, with two main stations of assessment (pre- and post-treatment), to compare between both outcomes. Results: Nine patients (18%) developed respiratory symptoms during this regimen, in the form of cough (16%), sputum production (6%), dyspnea (6%), fever (6%), and rhinorrhea (4%). Their diagnoses were; acute bronchitis (2 patients), flu-like symptoms (2 patients), cough due to gastro-esophageal-reflux-disease (1 patient), mild airway hyper-responsiveness (1 patient), community-acquired pneumonia (1 patient), community-acquired pneumonia with para-pneumonic effusion (1 patient) and idiopathic pleural effusion (1 patient). They were managed without discontinuation of the regimen. Conclusion: Sofosbuvir plus daclatasvir regimen was generally safe on the respiratory system, and some patients developed manageable non-serious respiratory events during the course of treatment. | ||||
| Keywords | ||||
| Pulmonary; Respiratory; Hepatitis C; Sofosbuvir; Daclatasvir | ||||
|
Statistics Article View: 233 PDF Download: 305 |
||||
